Mobile

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneou...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-015845-21

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare the change in DAS28 from baseline to Week 24 for patients on tocilizumab (TCZ) vs adalimumab (ADA).

Critère d'inclusion

  • Adult Rheumatoid Arthritis (RA)

Liens